|1.||Jacobs, Michael R: 2 articles (10/2006 - 12/2004)|
|2.||Appelbaum, Peter C: 2 articles (10/2006 - 12/2004)|
|3.||Jafri, M A: 1 article (01/2005)|
|4.||Patel, M V: 1 article (01/2005)|
|5.||Jacobs, M R: 1 article (01/2005)|
|6.||De Souza, N J: 1 article (01/2005)|
|7.||Bozdogan, B: 1 article (01/2005)|
|8.||Pankuch, G A: 1 article (01/2005)|
|9.||Appelbaum, P C: 1 article (01/2005)|
|10.||Gupte, S V: 1 article (01/2005)|
12/01/2004 - "Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models."
01/01/2005 - "Animal model studies showed that WCK 771 had efficacy comparable to that of levofloxacin, by both the oral and subcutaneous routes, for systemic infection caused by three quinolone-susceptible isolates of pneumococci. "
10/01/2006 - "Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771."
12/01/2004 - "WCK 771 is not a substrate of the NorA pump, as evident from the lack of an effect of reserpine on the MICs and similar protective doses against infections caused by efflux-positive and -negative staphylococci. "
12/01/2004 - "The activity of WCK 771 was superior to those of moxifloxacin, vancomycin, and linezolid in a mouse cellulitis model of infection caused by one MSSA and two MRSA strains, with effective doses of 2.5 and 5 mg/kg for the MSSA strain and 10-fold higher effective doses for MRSA strains. "
12/01/2004 - "These studies have demonstrated the effectiveness of WCK 771, administered orally and parenterally, for the treatment of diverse staphylococcal infections in mice, including those caused by quinolone-resistant strains."
12/01/2004 - "WCK 771, the arginine salt of S-(-)-nadifloxacin, was evaluated in animal models of staphylococcal infection and in vitro. "
|4.||Body Weight (Weight, Body)
|9.||sparfloxacin (AT 4140)